The Effect of the CO2 Fractional Laser or Premarin Vaginal Cream on Improving Sexual Function in Menopausal Women: A Randomized Controlled Trial
Journal of Lasers in Medical Sciences,
Vol. 11 No. 3 (2020),
21 Tir 2020
,
Page 292-298
Abstract
Introduction:
Sexual dysfunction is a complex problem in postmenopausal women with a prevalence rate of 68 - 86 %. This study aimed to evaluate the effect of a fractional CO2 laser or vaginal cream on the improvement of sexual function in menopausal women.
Methods:
This is a two-group clinical trial study. Postmenopausal women with the inclusion criterion were enrolled and randomly divided into two groups of intervention (n=25) and control group (n=25). In the intervention group, the CO2 laser therapy was performed every month for three months, and in the control group, Premarin vaginal cream was applied (0.625 mg )، 1 gr, three nights a week for 3 months. Vaginal Health Index scoring( VHI) and Female Sexual Function Index( FSFI) questionnaires were completed before and after three months of treatment.
Results:
The effects of the laser treatment was greater than the Premarin group with respect to improvement in sexual desire, orgasms, sexual satisfaction, less pain during sexual relations, and overall sexual function. ( P<0.05)
Conclusion:
It seems that the fractional CO2 laser may be more effective than hormonal therapy in improving sexual function in postmenopausal women.
- CO2 laser
- Premarin
- Sexual function index
- Menopause
How to Cite
References
Lobo RA, Kelsey J, Marcus R, editors. Menopause: biology and pathobiology. San Francisco: Academic Press; 2000.
Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on the quality of life. Maturitas. 2009;63(2):138-41. doi: 10.1016/j.maturitas.2009.03.021.
Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163(3):888-93. doi: 10.1016/s0022-5347(05)67828-7.
Addis IB, Van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH. Sexual activity and function in middle-aged and older women. Obstet Gynecol. 2006;107(4):755-64. doi: 10.1097/01.AOG.0000202398.27428.e2.
Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387-395. doi: 10.2147/IJWH.S158913.
Sokol ER, Karram MM. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause. 2017;24(7):810-814. doi: 10.1097/GME.0000000000000839.
Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233-8. doi: 10.1016/j.maturitas.2010.08.001.
Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514-22. doi: 10.1111/j.1529-8019.2010.01354.x.
American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902. doi: 10.1097/GME.0b013e3182a122c2.
Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, et al. Definitions of women’s sexual dysfunction reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol. 2003;24(4):221-9. doi: 10.3109/01674820309074686.
Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279-85. doi: 10.1080/13697130902814751.
Long CY, A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause. 2006;13(5):737-43. doi: 10.1097/01.gme.0000227401.98933.0b.
Goldstein I. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med. 2005;2(Suppl 3):154-65. d: 10.1111/j.1743-6109.2005.00131.x.
Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol. 2005; 106(5 Pt 1):940-945. doi: 10.1097/01.AOG.0000180394.08406.15.
Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219-25. doi: 10.3109/13697137.2014.975197.
Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363-369. doi: 10.3109/13697137.2014.899347.
Salvatore S, Maggiore ULR, Origoni M, Parma M, Quaranta L, Sileo F, et al. Microablative fractional CO2 laser improves dyspareunia related to vulvovaginal atrophy: a pilot study. J Endometr Pelvic Pain Disord. 2014;6(3):150-6.
Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, et al. Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80(3):296-301. doi: 10.1016/j.maturitas.2014.12.006.
Pieralli A, Fallani MG, Becorpi A, Bianchi C, Corioni S, Longinotti M, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841-6. doi: 10.1007/s00404-016-4118-6.
Pearson A, Booker A, Tio M, Marx G. Vaginal CO2 laser for the treatment of
vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. Breast
Cancer Res Treat. 2019;178(1):135-140. doi: 10.1007/s10549-019-05384-9.
Fakhri A, Pakpour AH, Burri A, Morshedi H, Zeidi IM. The Female Sexual Function Index: translation and validation of an Iranian version. J Sex Med. 2012;9(2):514-23. doi: 10.1111/j.1743-6109.2011.02553.x.
Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, Ferrero S, Origoni M, Candiani M, and Leone Roberti Maggiore U. Sexual function after fractional microablative CO 2 laser in women with vulvovaginal atrophy. CLIMACTERIC 2014; 17:1–7
Eder SE. Early effect of fractional CO2 laser treatment in Post-menopausal women with vaginal atrophy. Laser Ther. 2018;27(1):41-47. doi: 10.5978/islsm.18-OR-04.
Salvatore S, Athanasiou S, Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol. 2015;27(6):504-8. doi: 10.1097/GCO.0000000000000230.
Siliquini GP, Tuninetti V, Bounous VE, Bert F, Biglia N. Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. Climacteric. 2017;20(4):379-384. doi: 10.1080/13697137.2017.1319815.
Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426-438. doi:10.1002/lsm.20048.
Peterson CM, Lane JE, Ratz JL. Successful carbon dioxide laser therapy for refractory anogenital lichen sclerosus. Dermatol Surg. 2004;30(8):1148-51. doi: 10.1111/j.1524-4725.2004.30343.x.
Lee A, Lim A, Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus. Australas J Dermatol. 2016;57(1):39-43. doi: 10.1111/ajd.12305.
Arroyo C. Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int J Womens Health. 2017;9:591-595. doi: 10.2147/IJWH.S136857.
Preti M, Vieira-Baptista P, Digesu GA, Bretschneider CE, Damaser M, Demirkesen
O, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document. J Low Genit Tract Dis. 2019;23(2):151-160. doi: 10.1097/LGT.0000000000000462.
Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017;99:10-5. doi: 10.1016/j.maturitas.2017.01.012.
- Abstract Viewed: 1027 times
- PDF Downloaded: 355 times